Advertisement

Topics

Companies Related to "Biogen inks deals with Therapeutics Skyhawk develop drugs" [Most Relevant Company Matches] RSS

14:21 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Biogen inks deals with Therapeutics Skyhawk develop drugs" found in our extensive corporate database of over 50,000 company records.

Showing "Biogen inks deals with Therapeutics Skyhawk develop drugs" Companies 1–25 of 4,900+

Relevant

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates ...


Biogen Idec and Portola Pharmaceuticals

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates ...

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and inno...


Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple scleros...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple scleros...

Biogen Inc.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its ...

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL). The com...

Biogen Incorporated

Biogen, Inc. is a biopharmaceutical company principally engaged in the business of developing, manufacturing and marketing drugs for human health care. The Company currently derives revenues from sales of its AVONEX(R) (Interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis and from sales by its licensees of a number of products, including alpha interferon, hepatitis B vacc...

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts of bioorganic chemistry. Our business idea is to improve treatment of common and serious diseases with focus on oncology. This is performed by development of the semi-synthetic substances discovered by the company into a new generation of efficient drugs for different therapeutic areas.A main ambition is to devel...

Xenova Group PLC

Xenova Group plc is an emerging pharmaceutical group, specialising in the development of new small molecule drugs. The company’s strategy is to develop commercially attractive new drugs, primarily in the area of cancer therapeutics.

Leafbuyer Technologies, Inc.

The most comprehensive online source for cannabis deals and specials, Leafbuyer.com connects consumers with dispensaries. Leafbuyer works alongside businesses to showcase their unique products and build a network of loyal patrons. Leafbuyer’s national network of cannabis deals and information reaches millions of consumers monthly. Leafbuyer is the off...

SkyePharma

SkyePharma uses world-leading drug delivery technology to make good drugs even better. We have the ability to solve over 90% of the industry's formulation and delivery challenges by drawing on the broadest-available range of drug delivery technologies, turning already-proven drugs into more effective and safer medicines. Combining our established pre-clinical, clinical and regulatory expertise wi...

VInternational Therapeutics, Inc.

International Therapeutics, Inc. (ITI) is a privately held Seattle biotechnology company focused on the discovery and development of novel anti-viral therapies. Currently the Company is dedicated to finding new, safe and effective ways to combat HIV, a virus infecting over 42 million people worldwide.ITI's novel technologies include nuclear entry inhibition and RNA intervention. For more informati...

ROMEG Therapeutics

ROMEG Therapeutics, LLC, a privately held specialty pharmaceutical company based in Woburn, Mass., was founded by Indu Muni and Gita Muni in 2015. The company’s mission is to develop new FDA-approved therapies by formulating novel dosage forms, improving the design and function of existing approved drugs, and expanding clinical indications for use of ...

OncoFusion Therapeutics, Inc.

OncoFusion Therapeutics is a privately-held company, which was founded in 2012 by Arul M. Chinnaiyan, M.D., Ph.D.; Shaomeng Wang, Ph.D., and Kenneth J. Pienta, M.D. to develop technology discovered at the University of Michigan. OncoFusion's mission is to discover and develop the next generation of personalized therapeutics for patients with genetically de...

EiRx Therapeutics Limited

The Company is based around original concepts and discoveries made by Prof. Tom Cotter (CSO). Tom is a leading international expert in this field and is Professor of Biochemistry at University College Cork. The goal of applied research in apoptosis is to develop new drugs that effectively modulate apoptosis in disease states in a safe manner. EiRx Therapeutics believes that there will be significa...

Somanta

Our mission is to be among the leading biotechnology companies, using expertise to develop, manufacture and commercialize cancer therapeutics that address significant unmet medical needs in oncology. We are committed to high standards of integrity and to contribute to the best interests of patients, doctors, our employees, and to seeking significant returns to our stockholders, based on the contin...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therapeutics’ lead product is AIR645, the first in a new class of inhaled drugs that incorporate proprietary, second-generation antisense chemistry. www.altairthera.com

Ys Therapeutics Co., Ltd

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs.Our mission is to improve QOL (quality of life) for patients, their families and friends by developing innovative drugs.goal is to become an unchallenged citizen in the worldwide bio industry

Novosom AG

Novosom AG has solved the major obstacle towards DNA therapeutics: Delivery of the therapeutic principle towards the cell interior. Novosom and its partners develop unique DNA based therapeutics in inflammation, oncology and liver diseases. In addition, the company is developing its own pipeline in autoimmune diseases. In 2007, the company plans to file two INDs with partners (oncology and liver d...

Context Therapeutics

Context Therapeutics is a private, Philadelphia, PA-based biotechnology company dedicated to creating new medicines to treat Sigma1-associated diseases. The company leverages breakthrough science on the biochemistry of Sigma1 protein, the role of Sigma1 in regulating client protein homeostasis, and the role of Sigma1 in disease to develop novel drugs targe...

Irving Levin Associates, Inc.

Despite the uneven performance, some health care sectors turned in break-out performances, particularly on the services side. Home Health and Hospice recorded a 20.7% gain in deal volume (to 35 deals vs. 2011) and a whopping 1872.1% in dollar volume (to $5.7 billion vs. 2011). Typically deals in this sector are small, and conducted between private companie...

Mercator Therapeutics, Inc.

Mercator Therapeutics is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. Mercator was founded to translate the research of Drs. Wadih Arap and Renata Pasqualini into effective cancer therapeutics. Drs. Arap and Pasqualini pioneered the use of in vivo phage display to identify peptide...

Pepscan Therapeutics BV

Mercator Therapeutics is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. Mercator was founded to translate the research of Drs. Wadih Arap and Renata Pasqualini into effective cancer therapeutics. Drs. Arap and Pasqualini pioneered the use of in vivo phage display to identify peptides that are believed to selectively del...

MultiCell Technologies

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. MultiCell’s drug development program is focused on the modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, rel...


More From BioPortfolio on "Biogen inks deals with Therapeutics Skyhawk develop drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks